Note 14 - Net Income (Loss) Per Share - Antidilutive Securities Excluded from Computation (Details) - shares |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|
| Antidilutive securities (in shares) | 11,101,390 | 11,324,307 | 12,887,982 | 11,324,307 |
| Convertible Notes Payable [Member] | ||||
| Antidilutive securities (in shares) | 62,500 | 1,457,849 | 1,503,596 | 1,457,849 |
| Common Stock Warrants [Member] | ||||
| Antidilutive securities (in shares) | 7,760,247 | 6,818,518 | 7,910,247 | 6,818,518 |
| Share-Based Payment Arrangement, Option [Member] | ||||
| Antidilutive securities (in shares) | 3,278,643 | 2,681,534 | 3,474,139 | 2,681,534 |
| Restricted Stock [Member] | ||||
| Antidilutive securities (in shares) | 0 | 36,778 | 0 | 36,778 |
| Contingent Earnout Shares [Member] | ||||
| Antidilutive securities (in shares) | 0 | 329,628 | 0 | 329,628 |